Magnitude of the Quality Assurance, Quality Control, and Testing in the Shiraz Cohort Heart Study

Abstract

To determine the conclusive integrity in the Shiraz Cohort Heart Study (SCHS) project, management began quality assurance (QA) and quality control (QC) of the collected data throughout the study end-points. The QA is a focused process that prevents and detects data collection errors and verification of intended requirements in the SCHS. The QC is a subset of QA intended to capture errors in processing data through testing and preventive processes to identify problems, defects, or intended requirements. SCHS involved 10,000 males and females aged 40-70 over a 10-year follow-up period with cardiovascular diseases (CVDs) in the city of Shiraz, Iran. The study measured events and access to preventive care in Shiraz city. The SCHS identified unique barriers to select national study models in developing standardized measures related to variations in ethnicity, religion, cross-cultural considerations, and others. A suggested response to this problem was to develop a mechanism to standardize elements of the questionnaire, study design, and method of administration. This action was based on the geographically normal distribution of the Family Physician Health and Medical Services in Shiraz. Important QA and QC decisions were developed and adopted in the construction of the SCHS and follow-up to ensure conclusive integrity.

Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study

“…Additionally, 22.1% of the Shiraz cohort study population demonstrated intermediate-risk scores, while 3.4% showed high-risk scores. However, 13.2% and 2.5% of participants in our study, respectively, exhibited intermediate or high-risk scores (Table 5 ), indicating that Shiraz University employees are potentially less likely to develop ASCVD ( P < 0.001) [ 25 , 26 ].…”

“…This study enrolled 1191 Shiraz university employees and their spouses between the ages of 25 and 70 who were enlisted in a prospective cohort study in Shiraz (the capital of Fars province in southwest Iran) that began in 2018 and inducted 7643 participants (Shiraz Cohort Heart Study, SCHS) [ 25 , 26 ]. Additionally, 773 of 1191 participants were between 40 and 70 years old.…”

The prevalence of left ventricular hypertrophy associated with type-2 diabetes in Shiraz, Iran: a cross-sectional study

“…In this study, we applied QA-QC and Testing tools [ 34 ] to consider various possible components of related risk factors such as etiology of various clinical conditions, pathophysiology and numerous worldwide epidemiologic findings, that can lead to LVH in which increase in myocardial muscle mass based on ECG as a LVH diagnostic tool [ 1 – 10 ].…”

Potential of four definitions of metabolic syndrome to discriminate individuals with different 10-year cardiovascular disease risk scores: a cross-sectional analysis of an Iranian cohort

“…This study was a cross-sectional analysis of a prospective cohort which has been detailed elsewhere 30 31. In the current study, 7225 participants were screened against four different Mets definitions.…”